DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Exenatide (Byetta) Versus Pramlintide (Symlin): Role in Post-Prandial Hyperglycemia

Information source: Baylor College of Medicine
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Diabetes Mellitus, Type 1

Intervention: Insulin (Drug); Insulin and Exenatide (Drug); Insulin and Pramlintide (Drug)

Phase: Phase 3

Status: Enrolling by invitation

Sponsored by: Baylor College of Medicine

Official(s) and/or principal investigator(s):
Rubina A Heptulla, MD, Principal Investigator, Affiliation: Albert Einstein College of Medicine of Yeshiva University

Summary

The purpose of this study is to determine whether exenatide and pramlintide will improve blood glucose control after meals when compared to insulin alone.

Clinical Details

Official title: Exenatide (Byetta) Vs Pramlintide (Symlin): Role in Post-Prandial Hyperglycemia

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: To examine the effect of exenatide vs. pramlintide adjunctive therapy in addition to insulin on glycemic control in T1DM as compared to mono-therapy of insulin.

Eligibility

Minimum age: 12 Years. Maximum age: 21 Years. Gender(s): Both.

Criteria:

Inclusion Criteria: 1. Age of 12 to 21 years. 2. HbA1C less than 9% 3. Subjects must be on intensive insulin management 4. C-peptide less than 0. 3 ng/ml 5. Tanner stage greater than or equal to 3 6. Having T1DM for at least one year 7. T1DM defined by ADA criteria and having at least one of the following antibodies a. Anti-GAD (glutamic acid decarboxylase) b. Anti-islet cell 512 (ICA512) c. Anti-insulin 8. Willing to give consent. Exclusion Criteria: 1. Type 2 diabetes. 2. Having any other chronic condition except hypothyroidism stable on medications. 3. On chronic medications that may affect glucose excursions. 4. Anemia as defined as Hb less than 9 gm/dl. 5. Abnormal AST, ALT, amylase, lipase or creatinine (twice normal). 6. Unsupportive family environment as determined by clinicians and/or social workers. 7. Pregnant or lactating mothers

Locations and Contacts

Montefiore Medical Center CRC, Bronx, New York 10461, United States
Additional Information

Starting date: August 2009
Last updated: December 7, 2010

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017